PBM Act
Summary
The PBM Act (HR8779) would prohibit common ownership of pharmacy benefit managers and pharmacies, directly threatening the integrated business models of UnitedHealth, CVS Health, and Cigna. Although in early legislative stages, bipartisan sponsorship signals potential momentum.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.If passed, the bill forces divestitures of PBM or pharmacy assets from major integrated healthcare firms.
- 2.UnitedHealth, CVS Health, and Cigna face the highest structural and revenue risk.
- 3.Market pricing of this risk remains low due to early legislative stage; monitor committee activity.
Market Implications
The PBM Act introduces regulatory risk for the largest healthcare conglomerates. Currently, the market has not priced in this risk given the bill's early stage. If the bill gains traction—e.g., committee markup or bipartisan support grows—expect pressure on UNH, CVS, and CI as investors reassess the value of vertical integration. Conversely, independent pharmacies and PBM-focused companies without pharmacy ties could see relative benefit, but no such public companies are clearly isolated.
Full Analysis
The Patients Before Monopolies Act (PBM Act) was introduced on May 13, 2026, and referred to the House Committee on the Judiciary. It targets vertical integration in healthcare by barring PBMs and pharmacies from being under common ownership. The bill cites FTC findings that integrated PBMs steer patients to affiliated pharmacies, reducing competition and raising costs. No appropriation is involved; the bill imposes a structural prohibition. If enacted, UnitedHealth (UNH) would likely need to divest either OptumRx (PBM) or its Optum pharmacy network. CVS Health (CVS) would face a similar choice between Caremark (PBM) and CVS Pharmacy. Cigna (CI), through Express Scripts, would also be forced to spin off its PBM or exit pharmacy operations. Independent pharmacies could benefit from reduced self-preferencing, but no pure-play pharmacy tickers meet the causal chain threshold. The bill is early stage—only referred to committee—but has bipartisan sponsorship (7 cosponsors including both Republicans and Democrats). The legislative path requires committee markup, House passage, Senate consideration, and presidential action. Given the 119th Congress runs through 2027, there is time for development, but no immediate market impact is expected.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Prohibition of common ownership between PBM and pharmacy operations
Who must act
CVS Health (owns Caremark PBM and CVS Pharmacy retail chain)
What happens
Must divest either Caremark or CVS Pharmacy, disrupting integrated health services strategy and reducing profit from pharmacy benefit management
Stock impact
Caremark PBM and retail pharmacy together represent ~70% of CVS's revenue; forced separation would eliminate cross-segment efficiencies and potentially lower margins
What the bill does
Prohibition of common ownership between PBM and pharmacy operations
Who must act
Cigna (owns Express Scripts PBM and has pharmacy partnerships via Evernorth)
What happens
Must divest Express Scripts or exit pharmacy-related businesses, eliminating a key profit center and reducing bargaining power with drug manufacturers
Stock impact
Express Scripts accounts for ~60% of Cigna's total revenue; divestiture would remove the primary growth driver and lower EBITDA margins significantly
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Improving Seniors’ Timely Access to Care Act of 2025
PBM Act
Fair Care Act of 2026
To direct the Secretary of Labor to require group health plans include certain information on claim denials in annual reports, and for other purposes.
A bill to amend title 10, United States Code, to improve access to certain medications under the TRICARE program, and for other purposes.
Protecting Seniors and Stopping Fraudsters Act
Access to Genetic Counselor Services Act of 2025
Great American Healthcare Plan
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →